SOLICITATION NOTICE
65 -- Purchase of Fetal Bovine Serum
- Notice Date
- 3/13/2015
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC52539-83
- Archive Date
- 4/11/2015
- Point of Contact
- Gwennifer K. Epps, Phone: 240-276-5445, Terry Galloway, Phone: 240-276-5384
- E-Mail Address
-
eppsg@mail.nih.gov, gallowaytl@mail.nih.gov
(eppsg@mail.nih.gov, gallowaytl@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E136, Bethesda, MD 20892, UNITED STATES Description The National Cancer Institute (NCI), Laboratory of Tumor Immunology and Biology (LTIB) plans to procure on a sole source basis Fetal Bovine Serum, LOT#A49E00F from Gemini Bio-Products, 930 Riverside Parkway, Suite 50, West Sacramento, CA 95605 This acquisition will be processed in accordance with simplified acquisitions procedures as stated in FAR Part 13 13.106-1(b)(1) and is exempt for the requirements of FAR Part 6. The North American Industry Classification System code is 325414 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. Note: delivery shall be made within 30 days from date of award. The Laboratory of Tumor Immunology and Biology (LTIB), is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The laboratory conducts translational research in the areas of tumor immunology, immunotherapy, mechanisms of tumor cell-immune cell interactions, and immune mechanisms. The group also designs and develops immunotherapeutic and immunologic strategies for cancer treatment and prevention. Next, LTIB conducted analysis on the growth and immune assays on several different fetal bovine serum lots, submitted by different companies, and determined Gemini's Fetal Bovine Serum (FBS) Lot# A49E00F met the NCI's analysis requirement best. The choice of which serum selected for purchase was based on performance. Gemini's FBS met the requirements of the LTIB highest T-cell proliferation and lowest background proliferation. NCI considers Gemini Bio-Products sources of fetal bovine serum the best chosen serum for cell growth media to support immune assays and tissue culture requirements for the use by the entire laboratory of Tumor Immunology and Biology. The LTIB intends to purchase an entire lot (200 bottles) of Fetal Bovine Serum, LOT#A49E00F, to avoid the introduction of new variable in experimental results. In addition, changing variables would result in increased costs and incorrect interpretation of the immune assays which are currently in progress by the group. A sole source is intended for this order, based on the fact that Gemini collects raw serum only from countries that have been declared by the USDA to be free of specified bovine viruses. Each lot of the companies' fetal bovine serum is fully documented and certified as to its country of origin. Gemini works in close cooperation with the USDA to monitor FBS health and quality, employing an aggressive viral testing scheme to deliver only the safest and most well‐characterized products to its customers. This is not a solicitation for competitive quotations. However, if any interested party especially small business, believes they can meet the above requirement, they may submit a capability statement, proposal, or quotation which will be considered by the agency. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. Reponses must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on, March 27, 2015. All responses and questions must be in writing and can be faxed to (240) 276-5401 or emailed to Gwennifer Epps, at ge50d@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC52539-83 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC52539-83/listing.html)
- Place of Performance
- Address: National Cancer Institute, Clinical Center - Building 10, Bethesda, Maryland, 20814, United States
- Zip Code: 20814
- Zip Code: 20814
- Record
- SN03667362-W 20150315/150313234841-1e203efaf611b91f47f8648acd837b06 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |